A report should let a reader distinguish the selected product from similarly named targets, related analytes, alternative species records, and later catalogue updates. “ELISA kit for protein X” is usually not enough as an internal record. Preserve the product name as supplied, catalogue number, supplier or source, product identifier, target, stated application, species context where provided, and the product-page URL or other stable reference used during selection. If a field was not available or was not checked, say so rather than silently filling the gap.

This identity record is separate from the experiment record. The catalogue may describe the intended assay context; it does not, by itself, document how a particular plate behaved in your laboratory. Conversely, a clean-looking plate does not establish that the selected record was appropriate for every sample or species. Keeping the two records adjacent but distinct makes later review more disciplined.

Begin with the research question. Identify the analyte as precisely as the question permits, then check the species and sample context that matter to the planned work. A target name that appears similar across records should not be treated as evidence that the products are interchangeable. For a broader selection framework, see the ELISA assay selection guide. The purpose of that cross-reference is to support a selection decision; it is not a substitute for reading the product record and documenting the decision made.

For catalogue navigation, the supplied records illustrate why identity fields should be retained rather than shortened in a report. The Human Hemopexin ELISA Kit is recorded with catalogue number E-80HX, target Hemopexin, and stated application ELISA. The Human CRP ELISA Kit is recorded with catalogue number E-80CRP, target CRP, and stated application ELISA. These are catalogue references only. They do not establish comparative performance, suitability for a particular matrix, or an experimental result.

Describe how the standard observations were prepared and recorded, including the nominal values used for the calibration series and any dilution or preparation steps that affect their meaning. Preserve the raw standard signals alongside the fitted representation. If a standard was missing, visibly irregular, or removed from a fit, record the event and the reason. Avoid presenting a smooth curve as proof that every point was informative.

The calibration model should be identified in terms that another analyst can understand. State the model or transformation used, the range considered, the treatment of replicate standards, and the rule used to assess whether an unknown was within the reportable portion of the calibration. The appropriate model cannot be selected from appearance alone. Review the pattern of residuals or other model diagnostics used by your workflow, and explain what those observations did and did not justify.

Do not imply that a single goodness-of-fit value settles model adequacy. A model can appear visually strong while systematic deviations remain at one end of the range. Conversely, a point may look unusual for a reason that becomes clear when its preparation or plate position is reviewed. Report the evidence used in the decision, not only the decision itself. Readers should know whether the curve was accepted as planned, refit under a documented rule, or used only for a bounded exploratory calculation.

Precision should be described in context. Within-run variation concerns repeated measurements in the same run; between-run variation involves comparisons across runs and therefore introduces additional factors such as date, plate, operator, reagent preparation, instrument conditions, or other documented changes. Do not compare runs as though they were identical when those factors were not held constant or recorded.

Lot information deserves the same caution. If a study spans reagent or kit lots, record the lot identifiers and the allocation of samples and controls. If lot information is unavailable, state that limitation. A difference between runs may have several plausible explanations; the report should preserve the observations needed to investigate them rather than assigning an unsupported cause.

For related reading on evaluating curves without overstating what they show, see Evaluating ELISA Standard Curves Without Overstating the Data. For replicate-focused planning, the discussion of within-run and between-run precision provides a useful adjacent learning path.

Sample matrix can influence an assay’s observed signal independently of the analyte amount of interest. A practical report should identify the matrix, its preparation, dilution steps, storage and handling information available to the team, and any observations that led to additional checks. If the matrix was changed, diluted, pooled, heat-treated, or otherwise processed, preserve that information alongside the result.

Dilution behavior, spike recovery, and parallelism are useful concepts for organizing a validation investigation, but none should be treated as a universal pass/fail conclusion without a defined design and documented observations. A dilution series can reveal whether calculated results change coherently across dilutions. A spike experiment can show how a known addition behaves in the sample context. A parallelism comparison can examine whether sample and reference responses behave similarly across a relevant range. Report the design, observations, calculations, and boundaries; do not claim that one observation proves broad suitability.

Interference investigations should also record what was considered and what was not tested. If a sample contains components that may affect binding, signal generation, recovery, or measurement, describe the concern as a possibility unless the study directly evaluated it. The absence of an observed issue in one matrix and concentration range does not automatically establish the absence of interference elsewhere.

Species selection requires the same discipline. A similarly named analyte in a different species is not, by itself, evidence of cross-species suitability. Check the species stated in the product record, the target identity, reagent specificity information available in that record, and the documentation relevant to the research question. If cross-species use is being considered but was not evaluated, label it as an open verification question.

Category navigation can help organize this review without replacing product-level checks. Researchers comparing catalogue pathways may consult human ELISA kits and biomarker research ELISA kits, then return to the individual product record and study documentation. To keep catalogue discovery separate from scientific inference, the searchable Products page should be used to locate records, while the report should state the evidence actually reviewed.

Questions to answer before comparing results

• Were the same target definition, species context, and sample matrix used?
• Were preparation, dilution, storage, and handling conditions comparable?
• Were the same calibration boundaries and processing rules applied?
• Were controls and replicate structures comparable across runs?
• Could a lot, plate, operator, date, or instrument difference explain part of the variation?
• Which differences were observed directly, and which are only hypotheses?